Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

3.81 (USD) • At close November 7, 2024
Bedrijfsnaam Zentalis Pharmaceuticals, Inc.
Symbool ZNTL
Munteenheid USD
Prijs 3.81
Beurswaarde 270,921,480
Dividendpercentage 0%
52-weken bereik 2.66 - 18.07
Industrie Biotechnology
Sector Healthcare
CEO Dr. Kimberly Lynn Blackwell M.D.
Website https://zentalis.com

An error occurred while fetching data.

Over Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors;

Vergelijkbare Aandelen

Revolution Medicines, Inc. logo

Revolution Medicines, Inc.

RVMD

59.1 USD

Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc.

CLDX

26.47 USD

Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc.

PACB

2.45 USD

Clover Health Investments, Corp. logo

Clover Health Investments, Corp.

CLOV

3.67 USD

Cronos Group Inc. logo

Cronos Group Inc.

CRON

2.06 USD

Prothena Corporation plc logo

Prothena Corporation plc

PRTA

17.49 USD

Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc.

CTKB

7.22 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)